**3. Results**

## *3.1. IR Experiments*

The rosiglitazone (50 μM for 2 × 5 min) given before IR did not have a significant e ffect on myocardial function during its administration except for reversibly increasing coronary flow (Table 1). The infarct size was significantly increased in the rosiglitazone-treated hearts, but there was no significant positive or negative di fference in the functional outcome after IR between the rosiglitazone-treated and control hearts.

**Table 1.** Myocardial Function and Infarct Size. This table shows myocardial function during the application of the thiazolidinedione rosiglitazone (Rosi, 50 μM, n = 5), and myocardial function and infarct size at 120 min reperfusion following 30 min global no-flow ischemia compared to control (Con, n = 7) rat isolated hearts.


bl = baseline; LVP = left ventricular pressure; sys = systolic; dia = diastolic; dev = developed; RPP = rate-pressure product; dLVP/dtmax = contractility; dLVP/dtmin = relaxation; HR = heart rate; CF = coronary flow; IS = ventricular infarct size. All values are mean ± standard error of the mean of %bl unless otherwise indicated. Statistics: unpaired student *t*-test with \* *P* < 0.05 (two-tailed).
